Advanced chronic heart failure:: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

被引:283
作者
Metra, Marco
Ponikowski, Piotr
Dickstein, Kenneth
McMurray, John J. V.
Gavazzi, Antonello
Bergh, Claes-Hakan
Fraser, Alan G.
Jaarsma, Tiny
Pitsis, Antonis
Mohacsi, Paul
Boehm, Michael
Anker, Stefan
Dargie, Henry
Brutsaert, Dirk
Komajda, Michel
机构
[1] Univ Brescia, Sect Cardiovasc Dis, Dept Expt & Appl Med, I-25121 Brescia, Italy
[2] Mil Hosp, Dept Cardiol, Wroclaw, Poland
[3] Univ Bergen, Stavanger Univ Hosp, Div Cardiol, Stavanger, Norway
[4] Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland
[5] Osped Riuniti Bergamo, Dept Cardiol, I-24100 Bergamo, Italy
[6] Sahlgrens Univ Hosp, Dept Cardiol, S-41345 Gothenburg, Sweden
[7] Univ Wales Coll Cardiff, Coll Med, Dept Cardiol, Wales Heart Res Inst, Cardiff, Wales
[8] Univ Groningen Hosp, Dept Cardiol, Programme Coordinator COACH, Groningen, Netherlands
[9] St Lukes Hosp, Dept Cardiac Surg, Panorama Thessaloniki, Greece
[10] Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr Bern Head Heart Failure & Ca, CH-3010 Bern, Switzerland
[11] Univ Saarlandes Kliniken, Homburg, Germany
[12] Virchow Klinikum, Dept Cardiol, Berlin, Germany
[13] Univ London Imperial Coll Sci Technol & Med, NHLI, London, England
[14] Univ Glasgow, Western Infirm, Dept Cardiac, Glasgow G11 6NT, Lanark, Scotland
[15] Univ Antwerp, Dept Cardiol, AZ Middelheim Hosp, B-2020 Antwerp, Belgium
[16] Hop La Pitie Salpetriere, Dept Cardiol, Paris 13, France
关键词
heart failure; prognosis; treatment;
D O I
10.1016/j.ejheart.2007.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We propose a practical clinical definition and describe the characteristics of this condition. Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV); 2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown by at least one of the following: left ventricular ejection fraction < 30%, pseudonormal or restrictive mitral inflow pattern at Doppler-echocardiography; high left and/or right ventricular filling pressures; elevated B-type natriuretic peptides; 4) severe impairment of functional capacity demonstrated by either inability to exercise, a 6-minute walk test distance < 300 m or a peak oxygen uptake < 12-14 ml/kg/min; 5) history of > 1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives. (C) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:684 / 694
页数:11
相关论文
共 83 条
[1]   A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction [J].
Abdulla, J ;
Abildstrom, SZ ;
Christensen, E ;
Kober, L ;
Torp-Pedersen, C .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (07) :927-935
[2]   Clinical definition and epidemiology of advanced heart failure [J].
Adams, KF ;
Zannad, F .
AMERICAN HEART JOURNAL, 1998, 135 (06) :S204-S215
[3]   Digoxin and reduction in mortality and hospitalization in heart failure:: a comprehensive post hoc analysis of the DIG trial [J].
Ahmed, A ;
Rich, MW ;
Love, TE ;
Lloyd-Jones, DM ;
Aban, IB ;
Colucci, WS ;
Adams, KF ;
Gheorghiade, M .
EUROPEAN HEART JOURNAL, 2006, 27 (02) :178-186
[5]   Diastolic heart failure - A common and lethal condition by any name [J].
Aurigemma, Gerard P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (03) :308-310
[6]   Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [J].
Bardy, GH ;
Lee, KL ;
Mark, DB ;
Poole, JE ;
Packer, DL ;
Boineau, R ;
Domanski, M ;
Troutman, C ;
Anderson, J ;
Johnson, G ;
McNulty, SE ;
Clapp-Channing, N ;
Davidson-Ray, LD ;
Fraulo, ES ;
Fishbein, DP ;
Luceri, RM ;
Ip, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :225-237
[7]   PREDICTION OF MORTALITY AND MORBIDITY WITH A 6-MINUTE WALK TEST IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION [J].
BITTNER, V ;
WEINER, DH ;
YUSUF, S ;
ROGERS, WJ ;
MCINTYRE, KM ;
BANGDIWALA, SI ;
KRONENBERG, MW ;
KOSTIS, JB ;
KOHN, RM ;
GUILLOTTE, M ;
GREENBERG, B ;
WOODS, PA ;
BOURASSA, MG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (14) :1702-1707
[8]  
Bjornstad H, 2001, EUR HEART J, V22, P37
[9]   Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure [J].
Bristow, MR ;
Saxon, LA ;
Boehmer, J ;
Krueger, S ;
Kass, DA ;
De Marco, T ;
Carson, P ;
DiCarlo, L ;
DeMets, D ;
White, BG ;
DeVries, DW ;
Feldman, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2140-2150
[10]   Questions and answers about the STICH trial: A different perspective [J].
Buckberg, GD .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (02) :245-249